News

Public · Published

NeuroSense Therapeutics Ltd. (NRSN) Targets March 2027 Canadian Filing With New NfL Data

NeuroSense Therapeutics plans to submit an expanded application for its PrimeC candidate to Health Canada in March 2027, revising its previous December 2026 target. Health Canada said it had no concerns with the revised timing. The package is to include new NfL analysis and additional unpublished Phase 2b data.

Published:

Updated:

What happened

NeuroSense Therapeutics plans to submit an expanded application for its PrimeC candidate to Health Canada in March 2027, revising its previous December 2026 target. Health Canada said it had no concerns with the revised timing. The package is to include new NfL analysis and additional unpublished Phase 2b data.

Confirmed

Global impact / market context

The later filing target extends the wait before Health Canada can review PrimeC, while the added trial analysis may provide evidence for the application. Until the company submits it and receives a decision, PrimeC remains an unapproved candidate and cannot generate sales under this application.

Analyst inference

This is a planned regulatory filing, not an approval or completed submission. The release says the new NfL analysis showed a greater reduction than placebo, but gives no numerical effect size and says further statistical analyses are underway, leaving the evidence and timing to resolve.

Analyst inference

What to watch

  1. Watch whether NeuroSense submits the expanded PrimeC application to Health Canada in March 2027, the revised target that follows its earlier December 2026 plan. Analyst inference
  2. Look for the additional unpublished Phase 2b data and completed statistical analyses, which may clarify how the NfL result supports the application. Analyst inference
  3. Track Health Canada's review and any authorization decision after submission; the filing remains planned, and no approval has been reported. Analyst inference

Evidence

  • Original source link unavailable